Aposense Ltd.
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Public, Subsidiary
- Established
- 1996-01-01
- Employees
- 12
- Market Cap
- -
- Website
- http://www.aposense.com
Clinical Trials
4
Active:0
Completed:1
Trial Phases
1 Phases
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (100.0%)An Efficacy and Safety Study to Assess [18F]-ML-10 in Detecting Response of Tumors to Chemotherapy and Radiation
Phase 2
- Conditions
- Carcinoma, Non-Small-Cell LungHead and Neck Neoplasms
- First Posted Date
- 2010-12-15
- Last Posted Date
- 2010-12-17
- Lead Sponsor
- Aposense Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT01260480
- Locations
- 🇺🇸
BWH, Boston, Massachusetts, United States
🇺🇸Holy Name Medical Center, Teaneck, New Jersey, United States
🇺🇸Mount Sinai, New York, New York, United States
Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.
Phase 2
- Conditions
- Solid TumorsBrain Metastases
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2010-05-12
- Lead Sponsor
- Aposense Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT00805636
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Department of Radiation oncology, Memorial Sloan Kettering Cancer Center, New York city, New York, United States
18F ML-10 for Early Detection of Response of Brain Metastases to WBRT
Phase 2
Completed
- Conditions
- Solid TumorsBrain Metastases
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2013-02-13
- Lead Sponsor
- Aposense Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT00791063
18F ML-10 for Early Detection of Response of Brain Metastases to SRS
Phase 2
Terminated
- Conditions
- Metastasis to Brain of Unknown Primary
- Interventions
- Drug: ([18F]-ML-10)
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- Aposense Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT00696943
News
No news found